Science News
from research organizations
Anti-anginal Drug Safe But Not Effective In Reducing Major Cardiac Events In ACS Patients
- Date:
- April 26, 2007
- Source:
- JAMA and Archives Journals
- Summary:
- The anti-anginal medication ranolazine was shown to be safe in regard to certain outcomes but did not reduce the risk of major cardiovascular events such as death, heart attack or recurrent ischemia following acute coronary syndromes, according to a study in the April 25 issue of JAMA.
- Share:
FULL STORY
The anti-anginal medication ranolazine was shown to be safe in regard to certain outcomes but did not reduce the risk of major cardiovascular events such as death, heart attack or recurrent ischemia following acute coronary syndromes, according to a study in the April 25 issue of JAMA.
Story Source:
Materials provided by JAMA and Archives Journals. Note: Content may be edited for style and length.
Cite This Page:
JAMA and Archives Journals. "Anti-anginal Drug Safe But Not Effective In Reducing Major Cardiac Events In ACS Patients." ScienceDaily. ScienceDaily, 26 April 2007. <www.sciencedaily.com
JAMA and Archives Journals. (2007, April 26). Anti-anginal Drug Safe But Not Effective In Reducing Major Cardiac Events In ACS Patients. ScienceDaily. Retrieved October 10, 2025 from www.sciencedaily.com
JAMA and Archives Journals. "Anti-anginal Drug Safe But Not Effective In Reducing Major Cardiac Events In ACS Patients." ScienceDaily. www.sciencedaily.com
Explore More
from ScienceDaily
RELATED STORIES